Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a non-negligible rate of adverse events that may lead to treatment discontinuation and/or the onset of pneumonitis/interstitial lung disease (ILD) The aim of the study is to identify and describe potentially predictive markers related to the onset of relevant T-DXd-related toxicities
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta lub mężczyzna w wieku co najmniej 18 lat
- •Potwierdzony histologicznie złośliwy nowotwór piersi z dodatnim lub niskim/bardzo niskim poziomem białka HER2
- •Pacjent kwalifikujący się do leczenia lekiem T-DXd zgodnie ze standardową praktyką
- •Zgoda na pobranie próbek krwi do badań badawczych
✗ Disqualifies
- •Operacyjny rak piersi bez przerzutów
- •Brak chęci do pobrania dodatkowych próbek krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
European Institute of Oncolgy
Milan, Italy
Trial contact
Elisabetta Munzone, MD
Davide Merli, PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.